News and Events

Programs and providers of Obstetrics and Gynecology at Weill Cornell Medicine are often the focus of news stories and features appearing in major national media. We invite you to review some stories that typify the breakthrough accomplishments of our remarkable team and highlight the impact our care has had on patient’s lives.

Weill Cornell Medicine-Led Consortium Receives $13.5 Million to Expand Patient Data Network

Photo of a woman

The INSIGHT Clinical Research Network (CRN), a database of more than 23 million patient health records, has received $13.5 million in renewed funding from the Patient-Centered Outcomes Research Institute (PCORI).

The renewed funding will support efforts to lead and conduct research of national scope over the next four years, increasing capacity for observational studies, retrospective studies, clinical trials, machine learning and more. Additionally, the funding will foster new collaborations and enable investigators to securely pool patient data, upholding the highest level of patient confidentiality, to support research on a specific topic. With this support, researchers can investigate patient-centered ways to understand and treat conditions including depression, diabetes, breast cancer, heart disease and Alzheimer’s disease.

INSIGHT CRN is one of the largest urban clinical networks in the nation, bringing together eight academic centers in New York City and its metropolitan area, as well as Houston, Texas. Led by a team at Weill Cornell Medicine, INSIGHT’s data contributing collaborators include Columbia University Irving Medical Center, Montefiore Health System, Mount Sinai Health System, NewYork-Presbyterian, NYU Langone Health, Houston Methodist and most recently Stony Brook Medicine, which will add approximately 1.3 million patient records to the database.

Immune Tolerance to Gut Microbes Is Initiated by a Key Bacterial Sensor

purple and pink stained intestinal cells

Thousands of bacterial and other microbial species live in the human gut, supporting healthy digestion, immunity, metabolism and other functions. Precisely how these microbes are protected from immune attack has been unclear, but now a study led by Weill Cornell Medicine investigators has found that this immune “tolerance” to gut microbes depends on an ancient bacterial-sensing protein called STING—normally considered a trigger for inflammation. The surprising result could lead to new treatments for inflammatory bowel disease and other conditions involving gut inflammation.

In their study, reported June 16 in Immunity, the investigators focused on group 3 innate lymphoid cells (ILC3s), immune cells that dwell in the mucosal lining of the gut. Their previous research revealed ILC3s’ essential role in preventing immune attacks on gut bacteria. In the new study, they showed that this crucial function in ILC3s depends on STING—such that moderate STING signaling induces immune tolerance, whereas higher levels of STING signaling cause the deaths of ILC3s and the loss of tolerance.

Dr. Teresa Sanchez Awarded the Established Investigator Award from the American Heart Association

Teresa Sanchez

Dr. Teresa Sanchez, associate professor of pathology and laboratory medicine and associate professor of neuroscience in the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine, has been awarded the highly competitive Established Investigator Award from the American Heart Association.

The five-year, $550,000 grant supports mid-career investigators who have made impactful contributions to cardiovascular science and who demonstrate exceptional potential for continued innovation. Dr. Sanchez is investigating how dysfunction in the cerebral vasculature, the blood vessels of the brain, can contribute to strokes and dementia, conditions currently affecting more than 150 million people worldwide.

Early in her career, Dr. Sanchez noticed that the cerebral vasculature was often overlooked in conversations about brain health despite its fundamental role in supplying blood and oxygen to the brain. She has since dedicated her career to understanding the molecular mechanisms driving cerebrovascular dysfunction, work that is essential for developing novel effective therapies to prevent or treat these devastating diseases.